세계의 칸디다증 치료제 시장 보고서(2025년)

Candidiasis Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,219,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,990,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,761,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

칸디다증 치료제 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보이며 2029년까지 3.8%의 연평균 복합 성장률(CAGR)로 38억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 정밀의료에 대한 접근 방식, 세계 항진균제 관리 프로그램, 칸디다 오리스 유병률 증가, 항진균제 내성에 대한 세계 노력에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 약물 전달 기술의 발전, 원격 의료 및 원격 환자 모니터링, 환자 중심 치료, 병용 요법, 공동 연구 이니셔티브 등이 있습니다.

진균 감염증의 유병률 증가가 칸디다증 치료제 시장의 성장을 견인할 것으로 예상됩니다. 피부, 점막, 내장을 침범하는 진균 감염은 면역력이 저하된 사람에게 많이 나타납니다. 이러한 감염, 특히 칸디다증의 발병률 증가는 근본적인 병원균을 표적으로 하는 특수하고 효과적인 항진균제를 개발 및 제공할 수 있는 기회를 제공합니다. 이러한 약물은 증상 완화, 합병증 예방, 회복 촉진, 의료 환경에서의 칸디다 감염 확산 억제, 환자 예후 개선 등을 목표로 합니다. 예를 들어, 2024년 1월 미국 미네소타 대학교는 곰팡이 감염이 연간 375만 명 이상의 사망을 유발하고 있으며, 그 중 약 255만 명이 곰팡이 질환과 직접적으로 관련이 있다고 보고했습니다. 이에 따라 곰팡이 감염증 증가는 칸디다증 치료제 시장을 촉진할 것으로 예상됩니다.

임상시험 증가는 칸디다증 치료제 시장의 성장 궤도를 더욱 가속화할 것으로 예상됩니다. 임상시험은 인간을 대상으로 새로운 치료법, 중재, 약물 및 장치의 안전성과 유효성을 평가하기 위한 매우 중요한 연구입니다. 칸디다증 치료제 분야에서 이러한 임상시험은 잠재적 치료제의 안전성과 유효성을 테스트할 수 있는 체계적이고 엄격한 평가 플랫폼을 제공함으로써 중요한 역할을 하고 있습니다. 임상시험의 수는 미국 50개 주와 221개국에 걸쳐 2022년 399,499건에서 2023년 약 437,533건으로 급증했습니다. 이러한 증가는 칸디다증 치료제의 상황을 형성하는 임상시험의 모멘텀과 중요성이 증가하고 있음을 보여줍니다. 결과적으로 임상시험의 급증은 칸디다증 치료제 시장의 성장을 가속하는 중요한 요인으로 작용하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 칸디다증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업 분석
• 세계의 칸디다증 치료제 시장 : 성장률 분석
• 세계의 칸디다증 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 칸디다증 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 칸디다증 치료제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 칸디다증 치료제 시장 : 치료 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 약
• 수술
• 기타 치료법
• 세계의 칸디다증 치료제 시장 : 해부학 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 구강 칸디다증
• 칸디다 질염
• 피부 칸디다증
• 침습성 칸디다증
• 전신성 칸디다증
• 세계의 칸디다증 치료제 시장 : 투여 방법별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 주사
• 경구
• 기타 관리 방법
• 세계의 칸디다증 치료제 시장 : 환자 집단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 성인
• 소아과
• 세계의 칸디다증 치료제 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 홈케어
• 전문 클리닉
• 기타 최종사용자
• 세계의 칸디다증 치료제 시장 : 의약품별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 항진균제
• 국소 치료
• 전신 치료
• 세계의 칸디다증 치료제 시장 : 수술 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 외과적 절제
• 장기 적출
• 세계의 칸디다증 치료제 시장 : 기타 치료법별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 프로바이오틱스
• 가정 요법
• 라이프스타일 변경

제7장 지역별/국가별 분석

• 세계의 칸디다증 치료제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 칸디다증 치료제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 칸디다증 치료제 시장 : 경쟁 구도
• 칸디다증 치료제 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
  • Torrent Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc.
• GSK plc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Cipla Inc.
• Bruker Corporation
• Lupin Limited
• Galapagos NV
• Basilea Pharmaceutica Ltd.
• WOCKHARDT Limited

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 칸디다증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 칸디다증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 칸디다증 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Candidiasis, a fungal infection caused by the overgrowth of Candida species, commonly affects areas such as the mouth, throat, gut, and genital regions. The primary methods of treating candidiasis involve antifungal medications, which can be either topical (applied to the affected area) or oral (ingested), depending on the severity and location of the infection.

Candidiasis therapeutics encompass various treatment approaches, including medication, surgery, and other interventions. Medication involves the use of pharmaceutical drugs to manage or alleviate the condition. The treatments target specific anatomical sites such as oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis. These medications can be administered through various routes, including injectable, oral, and others, catering to both adult and pediatric patients. The end-users for these treatments include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The candidiasis therapeutics market research report is one of a series of new reports from The Business Research Company that provides candidiasis therapeutics market statistics, including candidiasis therapeutics industry global market size, regional shares, competitors with a candidiasis therapeutics market share, detailed candidiasis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the candidiasis therapeutics industry. This candidiasis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.19 billion in 2024 to $3.3 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs.

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.83 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives.

The increasing prevalence of fungal infections is expected to drive the growth of the candidiasis therapeutics market. Fungal infections, which affect the skin, mucous membranes, and internal organs, are more common in individuals with weakened immune systems. This growing incidence of infections, particularly candidiasis, creates opportunities for manufacturers to develop and provide specialized, effective antifungal drugs that target the underlying pathogens. These drugs aim to alleviate symptoms, prevent complications, promote recovery, reduce the spread of Candida infections in healthcare settings, and improve patient outcomes. For instance, in January 2024, the University of Minnesota, a U.S.-based research institution, reported that fungal infections cause more than 3.75 million deaths annually, with about 2.55 million deaths directly linked to fungal diseases. As a result, the rising number of fungal infections is expected to propel the candidiasis therapeutics market.

The increasing number of clinical trials is expected to further fuel the growth trajectory of the candidiasis therapeutics market. Clinical trials serve as pivotal research studies aimed at assessing the safety and efficacy of novel medical treatments, interventions, drugs, or devices in human subjects. Within the domain of candidiasis therapeutics, these trials play a crucial role by offering a systematic and stringent evaluation platform for testing the safety and effectiveness of potential treatments. As reported by ClinicalTrials.gov in May 2023, the number of registered clinical trials surged to around 437,533 in 2023, compared to 399,499 registered studies in 2022 across all 50 states of the United States and spanning 221 countries. This increase underscores the rising momentum and significance of clinical trials in shaping the landscape of candidiasis therapeutics. Consequently, the burgeoning number of clinical trials emerges as a key factor driving the growth of the candidiasis therapeutics market.

Leading companies operating within the candidiasis therapeutics market are dedicatedly engaged in developing innovative drugs, such as BREXAFEMME (ibrexafungerp tablets), aimed at mitigating the occurrence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) constitutes an oral, non-azole medication designed for the treatment of vulvovaginal candidiasis (VVC) and reducing the incidence of recurrent vulvovaginal candidiasis (RVVC), commonly known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a prominent US-based pharmaceutical company, secured approval from the US Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets). The medication targets Candida albicans, the fungus responsible for VVC, by obstructing its growth. Notably, BREXAFEMME is deemed a safe and effective treatment option for vulvovaginal candidiasis (VVC), available solely through prescription, with a recommended dosage of one 150-mg capsule taken orally once daily for a single day. This innovative drug stands as a promising advancement in addressing candidiasis, offering a viable treatment solution while navigating potential concerns related to adverse drug effects.

In May 2023, GSK plc, a prominent UK-based pharmaceutical company, finalized the acquisition of Licensing rights for ibrexafungerp from Scynexism Inc. in a transaction amounting to $90 million. This strategic acquisition grants GSK exclusive rights to further the development and commercialization of ibrexafungerp drugs, a groundbreaking antifungal medication designed for the treatment of vulvovaginal candidiasis (VVC). The acquisition is aimed at expediting the advancement and market availability of ibrexafungerp. Scynexism Inc., a notable US-based pharmaceutical company specializing in therapeutic solutions for fungal diseases, including candidiasis, initially developed this innovative medication.

Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the candidiasis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The candidiasis therapeutics market consists of revenues earned by entities by providing services such as medication services, diagnostic tests, consultation services, and medical monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The candidiasis therapeutics market also includes sales of topical creams and ointments, oral medications, medical devices, probiotics, nutritional supplements and antifungal medications that are used in providing these services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Candidiasis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on candidiasis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for candidiasis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The candidiasis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medication; Surgery; Other Treatments
• 2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
• 3) By Mode Of Administration: Injectable; Oral; Other Mode Of Administrations
• 4) By Patient Population: Adults; Pediatrics
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Medication: Antifungal Drugs; Topical Treatments; Systemic Treatments
• 2) By Surgery: Surgical Debridement; Organ Removal
• 3) By Other Treatments: Probiotics; Home Remedies; Lifestyle Modifications
• Companies Mentioned: Pfizer Inc.; Biocon Limited; Torrent Pharmaceuticals Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Candidiasis Therapeutics Market Characteristics

3. Candidiasis Therapeutics Market Trends And Strategies

4. Candidiasis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Candidiasis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Candidiasis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Candidiasis Therapeutics Market Growth Rate Analysis
• 5.4. Global Candidiasis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Candidiasis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Candidiasis Therapeutics Total Addressable Market (TAM)

6. Candidiasis Therapeutics Market Segmentation

• 6.1. Global Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis
• 6.3. Global Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Other Mode Of Administrations
• 6.4. Global Candidiasis Therapeutics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Pediatrics
• 6.5. Global Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Drugs
• Topical Treatments
• Systemic Treatments
• 6.7. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Debridement
• Organ Removal
• 6.8. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Probiotics
• Home Remedies
• Lifestyle Modifications

7. Candidiasis Therapeutics Market Regional And Country Analysis

• 7.1. Global Candidiasis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Candidiasis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Candidiasis Therapeutics Market

• 8.1. Asia-Pacific Candidiasis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Candidiasis Therapeutics Market

• 9.1. China Candidiasis Therapeutics Market Overview
• 9.2. China Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Candidiasis Therapeutics Market

• 10.1. India Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Candidiasis Therapeutics Market

• 11.1. Japan Candidiasis Therapeutics Market Overview
• 11.2. Japan Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Candidiasis Therapeutics Market

• 12.1. Australia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Candidiasis Therapeutics Market

• 13.1. Indonesia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Candidiasis Therapeutics Market

• 14.1. South Korea Candidiasis Therapeutics Market Overview
• 14.2. South Korea Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Candidiasis Therapeutics Market

• 15.1. Western Europe Candidiasis Therapeutics Market Overview
• 15.2. Western Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Candidiasis Therapeutics Market

• 16.1. UK Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Candidiasis Therapeutics Market

• 17.1. Germany Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Candidiasis Therapeutics Market

• 18.1. France Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Candidiasis Therapeutics Market

• 19.1. Italy Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Candidiasis Therapeutics Market

• 20.1. Spain Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Candidiasis Therapeutics Market

• 21.1. Eastern Europe Candidiasis Therapeutics Market Overview
• 21.2. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Candidiasis Therapeutics Market

• 22.1. Russia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Candidiasis Therapeutics Market

• 23.1. North America Candidiasis Therapeutics Market Overview
• 23.2. North America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Candidiasis Therapeutics Market

• 24.1. USA Candidiasis Therapeutics Market Overview
• 24.2. USA Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Candidiasis Therapeutics Market

• 25.1. Canada Candidiasis Therapeutics Market Overview
• 25.2. Canada Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Candidiasis Therapeutics Market

• 26.1. South America Candidiasis Therapeutics Market Overview
• 26.2. South America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Candidiasis Therapeutics Market

• 27.1. Brazil Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Candidiasis Therapeutics Market

• 28.1. Middle East Candidiasis Therapeutics Market Overview
• 28.2. Middle East Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Candidiasis Therapeutics Market

• 29.1. Africa Candidiasis Therapeutics Market Overview
• 29.2. Africa Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Candidiasis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Candidiasis Therapeutics Market Competitive Landscape
• 30.2. Candidiasis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Torrent Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Candidiasis Therapeutics Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Bayer AG
• 31.3. Novartis AG
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc.
• 31.6. GSK plc.
• 31.7. Amgen Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Astellas Pharma Inc.
• 31.10. Cipla Inc.
• 31.11. Bruker Corporation
• 31.12. Lupin Limited
• 31.13. Galapagos NV
• 31.14. Basilea Pharmaceutica Ltd.
• 31.15. WOCKHARDT Limited

32. Global Candidiasis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Candidiasis Therapeutics Market

34. Recent Developments In The Candidiasis Therapeutics Market

35. Candidiasis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Candidiasis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Candidiasis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Candidiasis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료